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Abstract
Background: Retention time (time to treatment failure) is a commonly used outcome in
antiepileptic drug (AED) studies.
Methods: Two datasets are used to demonstrate the issues in a competing risks analysis of AEDs.
First, data collection and follow-up considerations are discussed with reference to information
from 15 monotherapy trials. Recommendations for improved data collection and cumulative
incidence analysis are then illustrated using the SANAD trial dataset. The results are compared to
the more common approach using standard survival analysis methods.
Results: A non-significant difference in overall treatment failure time between gabapentin and
topiramate (logrank test statistic = 0.01, 1 degree of freedom, p-value = 0.91) masked highly
significant differences in opposite directions with gabapentin resulting in fewer withdrawals due to
side effects (Gray's test statistic = 11.60, 1 degree of freedom, p = 0.0007) but more due to poor
seizure control (Gray's test statistic = 14.47, 1 degree of freedom, p-value = 0.0001). The significant
difference in overall treatment failure time between lamotrigine and carbamazepine (logrank test
statistic = 5.6, 1 degree of freedom, p-value = 0.018) was due entirely to a significant benefit of
lamotrigine in terms of side effects (Gray's test statistic = 10.27, 1 degree of freedom, p = 0.001).
Conclusion: Treatment failure time can be measured reliably but care is needed to collect
sufficient information on reasons for drug withdrawal to allow a competing risks analysis. Important
differences between the profiles of AEDs may be missed unless appropriate statistical methods are
used to fully investigate treatment failure time. Cumulative incidence analysis allows comparison of
the probability of failure between two AEDs and is likely to be a more powerful approach than
logrank analysis for most comparisons of standard and new anti-epileptic drugs.
Background
Patients with a new diagnosis of epilepsy are usually pre-
scribed an antiepileptic drug (AED) as monotherapy [1,2].
An AED would be considered successful if the person tak-
ing it becomes seizure free with few side effects. Treat-
ments that cause unacceptable side effects are likely to be
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control seizures will either be changed to an alternative, or
a second drug will be added. In order to assess this meas-
ure of failure in randomised trials (RCTs) of AEDs, a pri-
mary outcome recommended by the International League
Against Epilepsy is retention time on AED [3], a compos-
ite outcome [4,5], defined as the time from randomisa-
tion to the withdrawal of the randomised AED or addition
of another.
Overall retention on treatment, i.e. time to treatment fail-
ure for any reason, may be analysed using standard sur-
vival analysis methods [6] and such analyses are common
in the AED field in both studies of monotherapy [7-14]
and add-on therapy [15,16]. However this approach fails
to examine different reasons for treatment failure (such as
inadequate seizure control or adverse events), and
assumes that reasons for failure are of equal importance
which may not be the case. For example the loss of a driv-
ing license due to continued seizures will have differing
social and economic consequences to the more common
side effects such as nausea, dizziness or rash. A situation
could arise in which two AEDs are considered equivalent
as a result of similar overall treatment failure when in fact
the drugs have very different effects on withdrawal due to
side effects and poor seizure control.
In the statistical literature, the situation where there are
several reasons why an event can occur is known as 'com-
peting risks'. Ignoring this aspect of an outcome by analys-
ing events overall can result in misleading conclusions
[6]. Some authors have examined separately the time to
withdrawal due to side effects [16] and have censored
patients whose allocated treatment is changed due to
inadequate seizure control, which may give misleading
results as analyses assume that the competing risks of
withdrawal are independent [6]. This assumption is ques-
tionable for AED treatment where there may be an associ-
ation between these two causes of treatment failure. Thus
a full investigation of retention time should include statis-
tical methods that do not assume the competing risks of
withdrawal are independent.
This paper considers the implications of competing risks
of treatment failure for the design, data collection and
analysis of AED studies motivated by analysis of the
SANAD (Standard And New Anti-epileptic Drugs) trial
[17] and drawing on our experience of datasets from our
programme of individual patient data meta-analyses
(IPDMA). We make recommendations for improving
research practice.
Methods
Treatment failure time
The definition of treatment failure time used in this paper
is the time from randomisation to the intention to with-
draw the randomised drug due to lack of efficacy (poor
seizure control) and/or intolerable side-effects; or the
addition of other AEDs whichever is the earliest. The date
of intention to withdraw rather than completion of with-
drawal was chosen to reflect the point at which the treat-
ment policy had been changed. Although retention time
is the usual term for this outcome, a more appropriate
alternative is time to treatment failure since it better
reflects the event of interest. It also encompasses the situ-
ation when an AED is added as a result of poor seizure
control and not just treatment failures resulting in the
withdrawal of the original drug. Patients who achieve a
period of seizure freedom (usually 2 to 3 years) may
decide to withdraw treatment, in this circumstance the
withdrawal reflects a successful outcome (seizure remis-
sion) rather than a treatment failure and the withdrawal is
not counted as an event. Since remissions occur later in
the follow-up period than withdrawals due to treatment
failure, such censoring has no effect on the analysis.
Participants
Two datasets are used to demonstrate the issues in a com-
peting risks analysis of AEDs. First, data collection, termi-
nology and follow-up considerations are discussed with
reference to information from a monotherapy meta-anal-
ysis. Recommendations for improved data collection and
analysis methods are then illustrated using the SANAD
dataset.
Individual patient data meta-analysis dataset
Information on treatment failure time was available from
15 randomised trials [18-31] involving 3883 individuals,
collected as part of a suite of individual patient data meta-
analyses concerning six different AEDs [7-14].
SANAD dataset
The design and analysis of this trial have been published
elsewhere [17]. For illustration here, we present the results
from a competing risks analysis of the data for two pair-
wise comparisons, (i) gabapentin (GBP) versus topiram-
ate (TPM) and (ii) lamotrigine (LTG) versus
carbamazepine (CBZ).
Design issues
Table 1 summarises the information collected on reason
for treatment failure in the 15 trials where we had
obtained the individual patient data. There was no stand-
ard approach for collecting this information and the level
of detail recorded varied across the studies. For this rea-
son, no analysis of competing risks has been undertaken
for these data in the relevant meta-analyses. In some trials,Page 2 of 10
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recorded. In others, several reasons were recorded along
with order of importance. Occasionally, a further variable
was recorded which indicated whether the clinician con-
sidered the reason for withdrawal to be related to the AED
or not.
In some trials patients may have been recorded as having
withdrawn for both side effects and poor seizure control.
In clinical practice, if a patient is still experiencing seizures
the dose of medication is increased until either seizures
are controlled or side effects occur that prevent further
dose increases. In the latter case, treatment will be with-
drawn because of both inadequate seizure control and
side effects. Since the former is the primary reason for fail-
ure, patients are classified as failures due to inadequate
seizure control. Some patients will reach maximum doses
without control of seizures and without significant side
effects. Pragmatically, the clinician would call this inade-
quate seizure control.
Table 1 shows that the percentage of patients for whom
the reason for treatment failure was unclear varied from 0
to 15%, but as a proportion of the number of withdrawals
ranged as high as 70%. Recording the reason for AED
withdrawal as non-compliance is not sufficient. Non-
compliance may be as a result of side effects or possibly
poor seizure control. Alternatively it may be due to a rea-
son unrelated to the efficacy or tolerability of the drug.
Thus to classify correctly the information in both an over-
all treatment failure analysis and a competing risks analy-
sis requires more information to be obtained.
As a result of the problems identified in data collection in
previous trials, extra detail regarding treatment failure rea-
son was sought in the SANAD study. Table 2 shows the
categories for reason for withdrawal recorded in SANAD,
together with whether the withdrawal was coded as an
event, and if so the reason for withdrawal (ISC or UAE),
or as a censored observation in the competing risks anal-
ysis of treatment failure time.
Statistical analysis
Standard survival analysis methods such as Kaplan-Meier
survival curve estimation, logrank hypothesis testing and
Cox regression modelling can all be applied validly to the
analysis of overall treatment failure time. However Kap-
lan-Meier estimates of being event free for a specific cause
will be biased if the assumption that the competing risks
are independent is violated. Kaplan-Meier curves are pre-
sented in this paper for illustration only however they
cannot be interpreted in terms of survival probabilities in
the presence of dependent censoring. We describe an
alternative approach, cumulative incidence analysis,
which makes no such assumption and allows the assess-
ment of cause-specific withdrawal in the presence of other
competing risks in the Appendix.
If all events of one type occur after the last event of
another type, the standard survival analysis methods such
Table 1: Classification of reasons for treatment change in 15 monotherapy trials
Trial Still on drug 
at end of 
follow-up 
(censored)
Reason for withdrawal
Adverse
events
Seizure
control
Remission Seizure
control and
adverse
events
Unclear Total 
number of 
patients in 
trial
Heller et al., 199518 131 25 29 36 15 7 243
De Silva et al., 199619 41 9 35 59 19 4 167
Mattson et al., 198520 312 25 16 0 108 14 475
Mattson et al., 199221 291 68 50 0 0 71 480
Richens et al., 199422 196 37 34 0 2 23 292
Verity et al., 199523 175 23 30 0 11 7 246
Brodie et al., 1995a24 85 40 3 0 2 6 136
Brodie et al., 1995b24 90 28 4 0 0 2 124
Ramsay et al., 199225 112 10 3 0 0 11 136
Turnbull et al., 198526 97 5 20 0 0 18 140
Placencia et al., 199327 159 10 0 0 0 23 192
Brodie et al., 199928 106 40 2 0 2 0 150
Bill et al., 199729 239 22 2 0 0 24 287
Guerreiro et al., 199730 158 16 7 0 1 11 193
Nieto-Barrera et al., 200131 534 70 18 0 0 0 622Page 3 of 10
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results to those obtained following the cumulative inci-
dence approach. Thus as a first stage of data analysis, it is
important to understand the time distribution of the var-
ious causes for withdrawal.
Cumulative incidence analysis, including hypothesis test-
ing, is available as part of the 'cmprsk' module [32] within
the R software package. Version 2.1–5 was used for the fol-
lowing analyses.
Results
Figure 1 shows how the distributions of withdrawal times
due to side effects and poor seizure control in the SANAD
trial overlap thus indicating the need to consider a cumu-
lative incidence approach.
Figure 2 gives results for overall treatment failure for CBZ
and LTG when the two causes, side effects and poor sei-
zure control, are not distinguished as events. The logrank
test statistic is 5.6 (1 df, p-value = 0.018) indicating LTG is
better retained than CBZ. Figure 3 considers withdrawal
for side effects as the only event, but censors withdrawals
for poor seizure control at the time of withdrawal. The
logrank test statistic is 10.4 (1 df, p-value = 0.001). There
is clear evidence that LTG is better tolerated than CBZ with
differences emerging very early on. Figure 4 considers
withdrawal for poor seizure control as the only event, but
censors withdrawals for side effects at the time of with-
drawal. The logrank test statistic is 0.02 (1 df, p-value =
0.89) and shows LTG to be equivalent to CBZ in terms of
seizure control.
Figure 5 gives results for overall treatment failure for GBP
and TPM. The logrank test statistic is 0.01 (1 df, p-value =
Distribution of withdrawal times for various reasons in the SANAD trialFigure 1
Distribution of withdrawal times for various reasons 
in the SANAD trial. Censored denoted by full shading, 
Unacceptable Adverse Event by /, Inadequate Seizure Con-
trol by X.
0 500 1000 1500 2000 2500
0
20
40
60
80
100
120
140
Time to w ithdraw al (days)
Fr
eq
ue
nc
y
Table 2: Classification of reasons for treatment change used in the SANAD trial
Reason for withdrawal from drug or other drug added 
(earliest event)
Categorised as event (type classified as 
ISC or UAE) or censored in 'time to 
treatment failure' analysis
Number of patients
(CBZ, LTG, TPM and GBP)
Inadequate seizure control Event (ISC) 348
Unacceptable adverse events Event (UAE) 320
Perceived risk of adverse effect Event (UAE) 8
Remission of epilepsy categorised by patient1 (less than 12 
months' remission from seizures)
Event (UAE) 46
Remission of epilepsy categorised by clinician (any length) or 
patient (more than 12 months' remission from seizures)
Censored 88
Study withdrawal – consent withdrawn2 Censored 23
Death (unrelated to epilepsy)3 Censored 32
Death (related to epilepsy)3 Event (ISC) 3
Moved from area Censored 0
Patient non-compliant or patient decision4 Censored 12
Pregnant or planning pregnancy Censored 6
Other Censored 12
Still on drug at last follow-up Censored 597
Not epilepsy Excluded 16
1 Patients decision to withdraw before 12 months' freedom from seizures is likely to be highly influenced by side effects or perception of side effects
2 Study withdrawals are automatically checked to ensure that the patient wants to withdraw from study rather than from drug only
3 Blinded assessment to identify whether death is related or unrelated to epilepsy/AED to take place prior to analysis
4 Further information is sought if patient withdraws from drug due to "non-compliance" as the underlying reason could be unacceptable adverse 
events, inadequate seizure control or remission of epilepsy.Page 4 of 10
(page number not for citation purposes)
Trials 2007, 8:12 http://www.trialsjournal.com/content/8/1/120.91) indicating no overall difference between GBP and
TPM. Figure 6 considers withdrawal for side effects as the
only event, but censors withdrawals for poor seizure con-
trol at the time of withdrawal. The logrank test statistic is
9.6 (1 df, p-value = 0.002). There is clear evidence that
GBP is better tolerated than TPM with differences emerg-
ing very early on. Figure 7 considers withdrawal for poor
seizure control as the only event, but censors withdrawals
for side effects at the time of withdrawal. The logrank test
statistic is 9.3 (1 df, p-value = 0.002). There is clear evi-
dence that TPM improves seizure control compared to
GBP with differences emerging very early on.
Figures 8 and 9 show cumulative incidence plots for the
two competing risks. The test statistic [32] comparing
withdrawals due to side effects is 10.27 (1 df, p-value =
0.001). The test statistic comparing withdrawals due to
poor seizure control is 0.78 (1 df, p-value = 0.38). The
plots show the probabilities of suffering a treatment fail-
ure due to an adverse event and of suffering a failure due
to inadequate seizure control in the setting where compet-
ing risks are acknowledged to exist. Thus at two years, for
LTG the chance of withdrawal due to adverse events is
20% and of withdrawal due to inadequate seizure control
is 15%, whilst for CBZ these probabilities are 30% and
13% respectively.
Kaplan-Meier distribution of time to withdrawal due to poor seizure cont ol fo  carbamazepine versus lamotrigineFig  4
Kaplan-Meier distribution of time to withdrawal due 
to poor seizure control for carbamazepine versus 
lamotrigine. Lamotrigine group denoted by triangle, car-
bamazepine by square.
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Kaplan-Meier distribution of overall treatment failure time for c rbamazep ne versus lamotrigineFigure 2
Kaplan-Meier distribution of overall treatment fail-
ure time for carbamazepine versus lamotrigine. 
Lamotrigine group denoted by triangle, carbamazepine by 
square.
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Kaplan-Meier distribution of time to withdrawal due to side effects for carbamazepine versus lamotrigineFigure 3
Kaplan-Meier distribution of time to withdrawal due 
to side effects for carbamazepine versus lamotrigine. 
Lamotrigine group denoted by triangle, carbamazepine by 
square.
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Cumulative incidence curves for withdrawal due to side effects for carbamaz pine versus lamotrigineFigure 8
Cumulative incidence curves for withdrawal due to 
side effects for carbamazepine versus lamotrigine. 
Lamotrigine group denoted by triangle, carbamazepine by 
square.
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Kaplan-Meier distribution of time to withdrawal due to side effects for gabapentin versus topiramateFigure 6
Kaplan-Meier distribution of time to withdrawal due 
to side effects for gabapentin versus topiramate. 
Gabapentin group denoted by circle, topiramate by line.
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Kaplan-Meier distribution of overall treatment failure time for g bap ntin versus t piramateFigure 5
Kaplan-Meier distribution of overall treatment fail-
ure time for gabapentin versus topiramate. Gabapen-
tin group denoted by circle, topiramate by line.
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Kaplan-Meier distribution of time to withdrawal due to poor seizure cont ol fo  gabapentin v rsus topiramateFig  7
Kaplan-Meier distribution of time to withdrawal due 
to poor seizure control for gabapentin versus topira-
mate. Gabapentin group denoted by circle, topiramate by 
line.
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Trials 2007, 8:12 http://www.trialsjournal.com/content/8/1/12Figures 10 and 11 show cumulative incidence plots for the
two competing risks. The test statistic [32] comparing
withdrawals due to side effects is 11.60 (1 df, p-value =
0.0007). The test statistic comparing withdrawals due to
poor seizure control is 14.47 (1 df, p-value = 0.0001). The
cumulative incidence analysis provides stronger evidence
of the advantage to GBP for side effects and TPM for sei-
zure control compared to the logrank approach. The plots
show the probabilities of suffering a treatment failure due
to an adverse event and of suffering a failure due to inad-
equate seizure control in the setting where competing
risks are acknowledged to exist. Thus at two years, for GBP
the chance of withdrawal due to adverse events is 19%
and of withdrawal due to inadequate seizure control is
32%, whilst for TPM these probabilities are 30% and 21%
respectively.
Discussion
Failure to investigate the competing risks of anti-epileptic
drug withdrawal can lead to important differences in the
clinical effect profiles of AEDs being missed. Thus overall
treatment failure could be similar for two AEDs when the
drugs have very different effects on withdrawal due to side
effects and poor seizure control. For a particular patient, it
is best to summarise each of these two risks for AEDs indi-
vidually, as well as considering the overall risk of with-
drawing for any reason. Further research is needed
Cumulative incidence curves for withdrawal due to poor sei-zure control for gabapentin versus opiramateFigure 11
Cumulative incidence curves for withdrawal due to 
poor seizure control for gabapentin versus topiram-
ate. Gabapentin group denoted by circle, topiramate by line.
0 1 2 3 4 5 6 7
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Time from randomisation (years)
C
um
ul
at
iv
e 
In
ci
de
nc
e 
P
ro
ba
bi
lit
y
GBP
TPM
Cumulative incidence curves for withdrawal due to poor sei-zure control for carbamaz pine versus lamotrigineFigure 9
Cumulative incidence curves for withdrawal due to 
poor seizure control for carbamazepine versus lamo-
trigine. Lamotrigine group denoted by triangle, car-
bamazepine by square.
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Cumulative incidence curves for withdrawal due to side effects for gabap tin ve su t piramateFigure 10
Cumulative incidence curves for withdrawal due to 
side effects for gabapentin versus topiramate. Gabap-
entin group denoted by circle, topiramate by line.
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ferent outcomes to individuals with epilepsy.
Prior to analysis, the timescale for competing causes
should always be investigated. Risks operating over differ-
ent time periods are less of an issue for the analysis. How-
ever, as demonstrated here, there is overlap of the
timescale for withdrawals due to the different reasons and
this is likely to be true for all AED studies.
More attention is required in the choice of statistical
methods employed for the analysis of the competing risks
of drug withdrawal. Cumulative incidence estimation
allows appropriate inference about the probability of fail-
ure of AEDs allowing for the presence of competing rea-
sons for such failure. This contrasts with the inappropriate
inference that is often made from one minus the Kaplan-
Meier estimate for a single failure reason which can only
be interpreted as a probability of failure in the hypotheti-
cal situation that other failure reasons are not possible.
Further, as suggested by a recent simulation study [33],
the cumulative incidence approach has greater power to
detect treatment differences than a logrank analysis in par-
ticular circumstances. This holds true for a difference in
one direction for one cause and no or an opposite differ-
ence for the other cause, a situation worthy of note for
anti-epileptic drug trials particularly when new and stand-
ard AEDs are being compared. Although conclusions from
the two methods of analysis were similar for both pairwise
comparisons shown here, this will not always be the case.
The reliability of classification of the cause of drug failure
must be assured before a competing risks analysis is
undertaken. The analysis of overall withdrawal is safe
since the information that a drug has been withdrawn is
usually reliable. For a competing risks analysis however,
the analyst must consider whether the classification of the
reason for withdrawal is reliable. The trials reviewed in
this paper varied in the level of detail collected. In partic-
ular, data on the reason for withdrawal needs to be as
accurate as possible for more explanatory research ques-
tions such as those posed in pharmacogenetic studies.
The dataset used for illustration here contained only two
patients for whom the reason for drug withdrawal was
recorded as non-compliance. Censoring the outcome for
these two individuals implicitly assumes that the reason
for non-compliance was not related to either seizure con-
trol or side effects. The results are likely to be robust to
such an assumption in this example due to the low
number of cases involved. However in other datasets
where this reason is recorded more frequently, some sort
of sensitivity analysis would be required to establish the
robustness of the conclusions to this assumption. One
approach would be to first code the withdrawal due to
non-compliance as an event then as a censored observa-
tion and assess the robustness of the conclusions to such
extreme assumptions. Of course ideally, as is the thrust of
this paper, one would wish to minimise such problems
through improved data collection methods.
Recommendations
The work presented here leads to the following recom-
mendations for future studies which include treatment
failure time as an outcome:
1) the outcome should be defined as the time to the inten-
tion to withdraw the randomised AED or add in another
(i.e. the point at which the treatment policy has been
changed),
2) sufficient detail should be collected on the primary rea-
son for drug withdrawal/addition to allow classification
into one of the following categories: withdrawal due to
unacceptable side effects, withdrawal due to inadequate
seizure control, withdrawal due to remission, withdrawal
due to a reason confirmed to be unrelated to either side
effects or seizure control.
The majority of drug withdrawals occurred by one year in
the SANAD dataset although two-year follow-up provides
greater power since almost all drug withdrawals occurred
by this time. Monotherapy studies need longer follow-up
however to investigate seizure control. Studies with both
treatment failure and remission outcomes should intend
to follow up each patient for a minimum of one year, and
ensure that a reasonable number of patients will provide
longer term follow-up, particularly important for seizure
outcomes. Finally, we recommend that this outcome be
termed 'time to treatment failure' rather than retention
time since the former better reflects the event of interest.
Authors' contributions
PRW identified the issue of competing risks in epilepsy tri-
als, investigated appropriate analysis methods, directed
the analyses, interpreted results and wrote the manuscript.
CTS carried out the statistical analyses, interpreted results
and contributed to writing the manuscript. JWS provided
data for analysis, provided clinical input and commented
on the manuscript. AGM provided data for analysis, pro-
vided clinical input and commented on the manuscript.
Appendix
The non-parametric cause-specific hazard function for
cause l is estimated by maximum likelihood via
h t
d
nl j
lj
j
( ) =Page 8 of 10
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Trials 2007, 8:12 http://www.trialsjournal.com/content/8/1/12where dlj represents the number of failures of type l at time
tj and nj is the number at risk at this time. The maximum
likelihood estimator of the cause-specific incidence at
time tj is
Il(tj) = P(T <tj, L = l) = S(tj-1)hl(tj)
where P(T <tj, L = l) is the probability that an individual
withdraws from drug due to cause l before tj and S(tj-1)
denotes the overall survival function at time tj-1 i.e. the
probability that an individual does not withdraw for any
reason before tj-1.
The cause-specific cumulative incidence function at time t
is then
where the summation is over each cause-specific event
time up to time t.
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